Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Sprint Bioscience AB's Enterprise Value is kr247.3 Mil.
Sprint Bioscience AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was kr70.5 Mil. Therefore, Sprint Bioscience AB's EV-to-OCF for today is 3.51.
The historical rank and industry rank for Sprint Bioscience AB's EV-to-OCF or its related term are showing as below:
OSTO:SPRINT'
s EV-to-OCF Range Over the Past 10 Years
Min: -15.67 Med: -2.05 Max: 722.58
Current: 3.45
During the past 13 years, the highest EV-to-OCF of Sprint Bioscience AB was 722.58. The lowest was -15.67. And the median was -2.05.
OSTO:SPRINT's EV-to-OCF is ranked worse than 80.13% of 1409
companies
in the Biotechnology industry
Industry Median: -3.6
vs OSTO:SPRINT: 3.45
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sprint Bioscience AB (OSTO:SPRINT) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sprint Bioscience AB's PE Ratio (TTM) for today is calculated as:
Sprint Bioscience AB's share price for today is kr3.37.
Sprint Bioscience AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.780.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Sprint Bioscience AB EV-to-OCF Related Terms
Sprint Bioscience AB EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Sprint Bioscience AB's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:SPRINT vs VRTX, REGN, RVMD: EV-to-OCF Comparison
For the Biotechnology subindustry, Sprint Bioscience AB's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sprint Bioscience AB EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sprint Bioscience AB's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Sprint Bioscience AB's EV-to-OCF falls into.
Sprint Bioscience AB's current Enterprise Value is kr247.3 Mil.
Sprint Bioscience AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr70.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sprint Bioscience AB (OSTO:SPRINT) has a EV-to-OCF of 3.51 as of Aug. 18, 2026. According to the industry distribution chart, Sprint Bioscience AB ranks #1129 out of 1409 companies in the Biotechnology industry, placing it in the top 80.1%.
Is Sprint Bioscience AB's EV-to-OCF too high?
Sprint Bioscience AB's current EV-to-OCF is 3.51. Based on the distribution chart, Sprint Bioscience AB ranks #1129 out of 1409 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sprint Bioscience AB has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Sprint Bioscience AB's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sprint Bioscience AB ranks #1129 out of 1409 companies for EV-to-OCF. This places Sprint Bioscience AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Sprint Bioscience AB's current EV-to-OCF is 3.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sprint Bioscience AB stock overvalued right now?
Sprint Bioscience AB (OSTO:SPRINT) has a current EV-to-OCF of 3.51. The current EV-to-OCF is 3.51. Sprint Bioscience AB's overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Sprint Bioscience AB (OSTO:SPRINT), the current EV-to-OCF is 3.51 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sprint Bioscience AB is a pharmaceutical company focused on developing drug candidates that can contribute to new treatments for cancer. Its product portfolio includes VRK1, VPS34, PETRA01, TREX1, NNMT, STK25, and DCPS. The company receives revenue for out-licensing drug programs, which include the development of a drug candidate.
22GF Score
Get the complete analysis for OSTO:SPRINT
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SPRINT has been successfully added to your 
